References
- Fernandez-OrtegaPCalotoMTChirvechesEChemotherapy-induced nausea and vomiting in clinical practice: impact on patient’s quality of lifeSupport Care Cancer2012203141314822460057
- National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®: Antiemesis Version 2.2015Fort Washington, PANational Comprehensive Cancer Network2015
- HaideraliAMendittoLGoodMTeitelbaumAWegnerJImpact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US populationSupport Care Cancer20111984385120532923
- NataleJReviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxisHosp Pract2015434226234
- PertweeRGEmerging strategies for exploiting cannabinoid receptor agonists as medicinesBr J Pharmacol200915639741119226257
- SlatkinNECannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesisJ Support Oncol20075Suppl 31917566383
- Marinol(R) [package insert]High Point, NCUnimed Pharmaceuticals, Inc2004
- MeiriEJhangianiHVredenburghEfficacy of dronabinol alone and in combination with ondansetron versus ondansetrom alone for delayed chemotherapy-induced nausea and vomitingCurr Med Res Opin200723353354317355735
- TodaroBCannabinoids in the treatment of chemotherapy-induced nausea and vomitingJNCCN201210448749222491047
- TramerMRCarrollDCampbellFAReynoldsJMMooreRAMcQuayHJCannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systemic reviewBMJ2001323162111440936
- RochaFMStefanoSCDe Cassia HaiekROliveiraLRSilveiraDDTherapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and metaanalysisEur J Cancer Care200817431443
- LaneMVogelCLFergusonJDronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomitingJ Pain Symptom Manage1991663523591652611
- HillKPMedical marijuana for treatment of chronic pain and other medical and psychiatric problems. A clinical reviewJAMA2015313242474248326103031
- SeamonMJFassJAManiscalco-FeichtlMAbu-ShraieNAMedical marijuana and the developing role of the pharmacistAm J Health Syst Pharm2007641037104417494903
- ChangAEShilingDJStillmanRCDelta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluationAnn Intern Med197991819824293141
- ChangAEShilingDJStillmanRCA prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapyCancer198147174617516261926
- MustyRERossiREffects of smoked cannabis and oral ∆9-trahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trialsJ Cannabis Therapeutics2001112956
- Solvay PharmaceuticalsDronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting NLM identifier: NCT00642512. Available from: https://clinicaltrials.gov/ct2/show/NCT00642512Accessed April 13, 2016
- National Cancer Institute and Solvay PharmaceuticalsM.D. Anderson Cancer CenterPalonosetron and dexamethasone with or without dronabinol in preventing nausea and vomiting in patients receiving chemotherapy for cancer NLM Identifier: NCT00553059. Available from: https://clinicaltrials.gov/ct2/show/NCT00553059Accessed April 13, 2016
- Solvay PharmaceuticalsDuke UniversityA pilot study of dronabinol for adult patients with primary gliomas NLM Identifier: NCT00314808. Available from: http://clinicaltrials.gov/show/NCT00314808Accessed April 13, 2016